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A B S T R A C T
Here we describe the case of a HIV-infected patient with polycystic kidney disease and end stage renal
diseases not transplantable due to the persistence of a CD4 count <200 notwithstanding a good
virological response to highly active antiretroviral therapy and suggest that such limitation to kidney
transplantation in such as cases might be bypassed.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
IDCases
journal homepage: www.elsevier .com/ locat e/ idcrAutosomal dominant polycystic kidney disease (ADPKD) is the
most common of the inherited cystic kidney diseases. It is
characterized by the development of renal cysts and various
extrarenal manifestations: cysts in the liver, seminal vesicles,
pancreas and arachnoid membrane. Other abnormalities, such as
intracranial aneurysms, mitral valve prolapse and abdominal wall
hernias can occur. Over 50% of patients with ADPKD eventually
develop end-stage renal disease (ESRD) and require dialysis or
kidney transplantation [1].
Human immunodeﬁciency virus (HIV) infected subjects, at the
same risk to develop ADPKD as the general population, are at
increased risk of developing acute kidney injury and chronic
kidney disease (CKD) [2–4]. Factors associated with an increased
risk of CKD in HIV infected individuals include older age, female
sex, diabetes, hypertension, injection drug use, low CD4+ cell
count, speciﬁc antiretroviral drugs and higher HIV RNA levels [5,6].
Additionally, HIV-HCV coinfection has been identiﬁed as a risk
factor for kidney disease in a number of studies and in a recent
meta-analysis [7]. Some reports have linked improvements in
kidney function or proteinuria to use of antiretroviral therapy and
suppressed HIV RNA levels [8]. Pathologic changes reported in HIV* Corresponding author at: UOC Malattie Infettive e Centro Regionale di
Riferimento, AIDS – AOU Policlinico, “P. Giaccone”, Università di Palermo Via del
Vespro, 129- 90127, Palermo, Italy.
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2214-2509/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unkidney biopsies include thrombotic thrombocytopenic purpura,
membranous nephropathy or membranoproliferative glomerulo-
nephritis (associated with hepatitis B or C coinfection and
syphilis), diabetic nephropathy, hypertensive glomerulosclerosis,
acute tubular necrosis, interstitial nephritis, postinfectious
glomerulonephritis, chronic pyelonephritis, and amyloid [9–11].
Here we describe the case of a HIV infected in a patient with
ADPKD and with dissociative viro-immunological responses to
highly active antiretroviral therapy (HAART) and suggest the
consideration of kidney transplantation for this category of
patients, regardless of CD4+ cell count.
Case
A 40-year-old homosexual man with history of ADPKD was
admitted to Palermo University Hospital in July 2012 complaining
of high fever, headache, and general malaise. Physical examination
showed oral candidiasis, seborrheic dermatitis, skin lesions on the
trunk compatible with Kaposi’s sarcoma and hepatosplenomegaly.
Blood tests on admission showed severe renal failure with a
creatinine clearance of 18 ml/min.
The abdomen CT scan showed bilateral multiple renal cysts that
were replacing the parenchyma (Fig.1).
HIV infection was diagnosed by enzyme-linked immunosorbent
assay (ELISA) and conﬁrmed with Western Blot assay. CD4+
lymphocyte T-count was 13 cells/mm3 (1.6%), with CD4/CD8 ratioder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computerized tomography of abdomen showing multiple bilateral renal
cysts.
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syphilis, toxoplasmosis, hepatitis B and C were negative.
The patient promptly started HAART with daily darunavir/
ritonavir 800/100 mg and abacavir/lamivudine 600/300 mg, and
prophylaxis for opportunistic infections with trimethoprim/
sulfamethoxazole 160/800 mg daily and azithromycin 1200 mg
once a week. After one month into HAART, the HIV-RNA load had
markedly decreased to less than 250 cpm and CD4+ count had
raised to 83 cells/mm3 (4.9%). During the follow up, the laboratory
tests showed a descending trend of creatinine clearance values and
metabolic acidosis.
In June 2014 HIV RNA level was undetectable and CD4+ count
was 187 cells/mm3 (17%) and, in anticipation of hemodialysis,
HAART with abacavir/lamivudine was replaced with raltegravir
400 mg twice a day due to raltegravir being removed by
hemodialysis only in minimal quantities.
The patient started hemodialysis three times a week in October
2014 and it was not possible to place him on the transplant list
because of a CD4+ cell count under 200 cells/mm3 despite
undetectable HIV RNA level [12]. Though virologically suppressed,
the patient has not yet been transplanted because his CD4+ count
remains below 200 cells/mm3.
Discussion
ESRD is a serious complication of chronic HIV infection that
carries signiﬁcant morbidity and mortality. Initially, HIV infection
was considered an absolute contraindication for transplantation
[13]. Since 1996 when HAART became widely available and the
prognosis of HIV infection dramatically improved, many transplant
programs have reevaluated the policies regarding the exclusion of
patients with HIV infection. Nowadays, kidney transplant has
become a viable alternative for HIV infected individuals with ESRD
since it is associated with better quality of life, fewer medical
complications, longer survival and lower cost than chronic dialysis
treatment [14–16]. Obviously, current indications and contra-
indications for transplantation also apply to HIV-infected patients.
In addition, a CD4+ cell count above 200 cells/mm3 is required for
all organs (with the exception of liver, that has a lower requirement
of 100 cells/mm3), as well as an undetectable HIV RNA level, and a
stable potent antiretroviral regimen for at least three months [12].
HAART allows the reconstitution of immune functions in most
treated HIV patients, but sometimes discrepant responses may
occur, including failure to achieve a signiﬁcant increase in
circulating CD4+ T cells despite undetectable plasma viral loads,with a substantially increased long-term mortality for all causes of
death [17]. The relevance of this case is to focus on the condition of
a viro-immunological dissociation which in fact does not allow the
inclusion in the transplant list. Our patient has not yet been
transplanted because, although he remains virologically sup-
pressed, his CD4+ count remain below 200 cells/mm3. Also,
hemodialysis could contribute to maintain the number of CD4+
cells low. Indeed, lymphopenia frequently occurs in hemodialysis
patients waiting for kidney transplantation; it could be related to
an increased turnover of lymphocytes, to a disturbance in
lymphocyte homeostasis due to uremia, and/or to increased
peripheral lymphocyte apoptosis associated with an activation
stimulus [18]. Indeed, a vicious cycle is established. In fact, ESRD is
associated with premature aging of the T-cell system [19], and even
if the consequence of ESRD related accelerated immunesenescence
are mostly unknown [20], it is reasonable that may worsen the
immunological status of the HIV infected patient.
For all these reasons we believe that lymphopenia should not
contraindicate kidney transplantation in selected HIV infected
patients with a CD4+ count <200 cells/mm3 if HIV RNA level is
undetectable and the patient is doing a stable potent antiretroviral
regimen. Several studies have shown that with sustained
suppression of viral replication, Pneumocystis jiroveci pneumonia
prophylaxis may not be necessary, regardless of CD4+ T-cell count
[21,22]. Furthermore it is known that HIV infection is associated
with a two- to threefold increased risk of rejection following
kidney transplant and that the administration of antithymocite
globulin (ATG) is used to reduce the risk of rejection to that of HIV
negative recipients even if it increase the risk of infective
complications [18,23].
A randomized clinical trial should be designed to investigate
whether patients with a CD4 count <200 cells/mm3 and undetect-
able HIV RNA level might beneﬁt from kidney transplantation and
whether ATG induction should or not be administered in these
cases.
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